Glucagon-like peptide-1 receptor agonists (GLP-1RA) (e.g., semaglutide, liraglutide) may also be of some benefit for patients with HF but their predominate role is in lowering the risk of stroke and peripheral artery disease and only modestly improving LVEF in HF patients [55,56,57,58,59,60,61]. This evidence concerns the gene GLP1R and stroke disorder.